|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/12/22 ABIOMED, Inc. 8-K:5 8/10/22 10:203K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 85K 5: R1 Document and Entity Information HTML 46K 8: XML IDEA XML File -- Filing Summary XML 11K 6: XML XBRL Instance -- abmd-20220810_htm XML 15K 7: EXCEL IDEA Workbook of Financial Reports XLSX 8K 3: EX-101.LAB XBRL Labels -- abmd-20220810_lab XML 40K 2: EX-101.PRE XBRL Presentations -- abmd-20220810_pre XML 33K 4: EX-101.SCH XBRL Schema -- abmd-20220810 XSD 11K 9: JSON XBRL Instance as JSON Data -- MetaLinks 11± 17K 10: ZIP XBRL Zipped Folder -- 0000950170-22-017121-xbrl Zip 18K
| 8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i August 10, 2022
i ABIOMED, Inc.
(Exact name of Registrant as Specified in Its Charter)
i Delaware |
i 04-2743260 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
i 22 Cherry Hill Drive
i Danvers, i Massachusetts
i 01923
(Address of Principal Executive Offices, including Zip Code)
( i 978) i 646-1400
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading symbol |
Name of each exchange on which registered |
i Common Stock, $0.01 par value |
i ABMD |
i The NASDAQ Stock Market LLC |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On August 10, 2022, ABIOMED, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company’s proxy statement filed in connection with the Annual Meeting: (1) the election of Michael R. Minogue, Martin P. Sutter and Paula A. Johnson each as a Class III director to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders; (2) the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers (as disclosed in the proxy statement filed in connection with the Annual Meeting); and (3) the ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2023.
The holders of 41,944,819 shares of common stock were present or represented by proxy at the Annual Meeting. The results of the votes for each of these proposals were as follows:
Proposal One: Election of Directors
Nominee |
|
Votes For |
|
Votes Withheld |
|
Broker Non-Votes |
|
Michael R. Minogue |
|
36,742,284 |
|
2,893,539 |
|
2,308,996 |
|
Martin P. Sutter |
|
22,443,240 |
|
17,192,583 |
|
2,308,996 |
|
Paula A. Johnson |
|
39,091,026 |
|
544,797 |
|
2,308,996 |
|
Proposal Two: Non-Binding, Advisory Vote on Executive Compensation
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
14,295,971 |
|
25,312,782 |
|
27,070 |
|
2,308,996 |
|
Proposal Three: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
41,427,426 |
|
502,960 |
|
14,433 |
|
0 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
ABIOMED, Inc. |
|
|
|
|
|
||
|
|
|
|
By: |
/s/ Marc A. Began |
|
|
|
|
|
Executive Vice President, General Counsel and Secretary |
Date: August 12, 2022 |
|
|
|
|
|
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 3/31/23 | ||||
| Filed on: | 8/12/22 | 4 | ||
| For Period end: | 8/10/22 | 4, DEF 14A | ||
| List all Filings | ||||